- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02073032
Incidence and Risk Factors of Refeeding Syndrome
Incidence and Risk Factors of Refeeding Syndrome in Head and Neck Cancer Patients - An Observational Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Consecutive patients referred to the Department of Otorhinolaryngology and Audiology on suspicion of cancer during the study period from February to August 2011. Patients were asked for participation if they met the following inclusion criteria: age ≥ 18 years, suspicion or diagnosis with HNC, and first time referral. Patients were excluded if not able to understand and speak Danish, having severe dementia and/or renal impairment (women: p-creatinine > 180 μmol/l, men: p-creatinine > 200 μmol/l).
Every participant was observed for eight days after admission or referral to the clinic. Blood samples and interviews were performed at baseline and at day 2, 4 and 7.
Potential factors defining high risk were analyzed by comparing those patients developing RFS or RFF with those that did not. Baseline information consisted of data from the interview and supplemental information in medical records. As a part of the interview, the participant was asked about dietary history in order to assess daily habitual energy end protein intake. Hand grip strength (HGS) was measured, and the participant performed a maximal step test on a 20 cm high bench. The nutritional status was evaluated using the NRS-2002 screening tool (13) and refeeding risk according to the NICE-guidelines (14). Intake of energy, protein, and fluids was registered and compared to the estimated requirements. Standardized questionnaires were used for the interviews, and blood samples were analyzed as part of daily routine in in-patients, while outpatients had their blood samples collected by their general practitioner or by accredited hospital laboratories close to their homes. For participants with a body mass index (BMI) < 30 kg/m2, energy requirement was calculated using Harris & Benedict's equations for men and women respectively (15). A physical activity factor of 1.1 for bedridden participants and 1.3 for non-bedridden participants was used. Protein requirement was calculated as 18 E-% of total energy requirement. For participants with a BMI ≥ 30 kg/m2 the following equations were used: Energy requirement (bedridden) = 85 kJ/kg body weight/day, energy requirement (non-bedridden) = 100kJ/kg body weight/day, protein requirement (bedridden) = 0.9 g/kg body weight/day, protein requirement (non-bedridden) = 1.1 g/kg body weight/day (16). Energy and protein intake was estimated from the 24-hour dietary recall by using the computer program "Dankost 3000" (Dankost 3000, version 2.5, Danish Catering Center, Herlev, Denmark).
For the step test, an audio file was used to dictate the rhythm, similar to the audio file used in The Danish Step Test (17). HGS was measured on the right hand with a hydraulic Jamar® hand dynamometer (scale 0-200 lbs). Three measurements were conducted with a break of 15 seconds between each measurement, and the mean value was used for analysis. Head and neck pain were measured twice by visual analogue scale (VAS) (18) with added marks for consistent pain and for pain during eating.
All statistical analyses were performed using STATA/IC 10.0 for Windows and Microsoft Excel 2003. The Mann-Whitney rank sum test was used for group comparisons, and dose-response relationships were tested by the Spearman's rank correlation test. Potential risk factors were analyzed by the Chi2-test with Yates correction or the Fisher's exact test as appropriate.
The primary outcomes were changes in p-phosphate and the development of RFS-symptoms after start of nutritional intake. A discriminative value for a clinically relevant hypophosphatemia or decline in p-phosphate was estimated from the coherence between the development of clinical symptoms and the lowest p-phosphate as well as the change in p-phosphate from baseline to the study day with the lowest p-phosphate value.
In case of significant differences between groups, odds ratios (OR) were calculated and Spearman's rank correlation test was used to test for correlation between the potential risk factor and change in p-phosphate, and correlations were tested for linearity by linear regression analysis. Sensitivity, specificity, and predictive values were calculated for NRS-2002 total score ≥ 3, NRS-2002 A-score = 1 and NICE guidelines, respectively.
The maximal increase in energy intake to be allowed without causing RFS was analyzed by correlating changes in p-phosphate and changes in intake in percentage of calculated energy requirements.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, 2100 Cph OE
- Clinic for Ear, Nose and Throat Surgery, Rigshospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Head and Neck Cancer
Exclusion Criteria:
- Not able to understand and speak Danish, having severe dementia and/or renal impairment (women: p-creatinine > 180 μmol/l, men: p-creatinine > 200 μmol/l).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Head -Neck cancer patients, no intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Decrease in plasma phosphate after start of feeding
Time Frame: 1 week
|
Plasma phosphate measured every day the initial day of feeding after admission
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occurence of relevant clinical symptoms along with a decrease in plasma phosphate
Time Frame: 1 week
|
Daily registration of symptoms: oedema, confusion, dyspnoea, hypotension, arrhythmia, seizures
|
1 week
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JRA-refeed-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer of the Head and Neck
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Bristol-Myers SquibbOno Pharma USA IncCompletedCancer of Head and Neck | Cancer of the Head | Cancer of the NeckJapan
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Washington University School of MedicineCelgene CorporationCompletedHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and Neck | Carcinoma, Squamous Cell of the Head and NeckUnited States
-
Bristol-Myers SquibbCompletedSquamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and NeckFrance
-
Royal Marsden NHS Foundation TrustRecruitingHead and Neck CancerUnited Kingdom
-
University of ChicagoCompletedHead and Neck CancerUnited States
-
Washington University School of MedicineTerminatedHead and Neck Cancer | Cancer of the Head and NeckUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHead and Neck Cancer | Cutaneous Squamous Cell Carcinoma of the Head and Neck | Healthy SubjectUnited States
Clinical Trials on No intervention, only observation
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
Association of Urologic Oncology (AUO)IAG-N at German Cancer Association (Deutsche Krebsgesellschaft e. V.)Recruiting
-
Sheba Medical CenterCompleted
-
Mackay Memorial HospitalCompleted
-
PfizerCompleted
-
Brigham and Women's HospitalMassachusetts Institute of Technology; Harvard UniversityCompleted
-
RwHealthNorthern Care Alliance NHS Foundation Trust; Alnylam PharmaceuticalsNot yet recruitingHereditary Amyloidosis | Guillain-Barre Syndrome | Chronic Inflammatory Demyelinating PolyneuropathyUnited Kingdom
-
Sun Yat-sen UniversityEssilor InternationalCompleted
-
Maaynei Hayesha Medical CenterRecruitingGeneration of Anti COVID-19 Antibodies in a Fetus, Whose Mother Was Exposed to COVID or Was Vaccinated During PregnancyIsrael
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedSmoking | Nicotine DependenceUnited States